Unknown

Dataset Information

0

Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.

ABSTRACT: Small-molecule-mediated disruption of the protein-protein interactions between acetylated histone tails and the tandem bromodomains of the bromodomain and extra-terminal (BET) family of proteins is an important mechanism of action for the potential modulation of immuno-inflammatory and oncology disease. High-quality chemical probes have proven invaluable in elucidating profound BET bromodomain biology, with seminal publications of both pan- and domain-selective BET family bromodomain inhibitors enabling academic and industrial research. To enrich the toolbox of structurally differentiated N-terminal bromodomain (BD1) BET family chemical probes, this work describes an analysis of the GSK BRD4 bromodomain data set through a lipophilic efficiency lens, which enabled identification of a BD1 domain-biased benzimidazole series. Structure-guided growth targeting a key Asp/His BD1/BD2 switch enabled delivery of GSK023, a high-quality chemical probe with 300-1000-fold BET BD1 domain selectivity and a phenotypic cellular fingerprint consistent with BET bromodomain inhibition.

SUBMITTER: Bradley E 

PROVIDER: S-EPMC10726358 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Small-molecule-mediated disruption of the protein-protein interactions between acetylated histone tails and the tandem bromodomains of the bromodomain and extra-terminal (BET) family of proteins is an important mechanism of action for the potential modulation of immuno-inflammatory and oncology disease. High-quality chemical probes have proven invaluable in elucidating profound BET bromodomain biology, with seminal publications of both pan- and domain-selective BET family bromodomain inhibitors  ...[more]

Similar Datasets

Unknown A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain.
| S-EPMC9618257 | biostudies-literature
Unknown Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation.
| S-EPMC7063807 | biostudies-literature
Unknown Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors.
| S-EPMC8232216 | biostudies-literature
Unknown Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
| S-EPMC3506127 | biostudies-literature
Unknown Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
| S-EPMC5789826 | biostudies-literature
Unknown Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells.
| S-EPMC10968860 | biostudies-literature
Unknown Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.
| S-EPMC4755933 | biostudies-literature
Unknown Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis.
| S-EPMC9278415 | biostudies-literature
Unknown The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
| S-EPMC5133849 | biostudies-literature
Unknown Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
| S-EPMC6489120 | biostudies-literature